Jan. 3, 2011
/PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that
, M.D., president and chief executive officer, will present at the 29th Annual J.P. Morgan Healthcare Conference on
Monday, January 10
10:30 a.m. Pacific Time
at the Westin St. Francis Hotel in
Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.
Live audio webcasts of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at
. A replay also will be available for 30 days following the live presentation.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at
SOURCE Medivation, Inc.